Prospective study of TNFα blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement

Nephrology Dialysis Transplantation

Volumn 25, Issue 10, 2010, Pages 3307-3314

  Laurino, Simona ^a   Chaudhry, Afzal ^b   Booth, Anthony ^b   Conte, Giuseppe ^a   Jayne, David ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

ANCA associated systemic vasculitis; Birmingham Vasculitis Activity Score (BVAS); induction of remission; safety; steroid sparing effect

Indexed keywords

ADALIMUMAB; CYCLOPHOSPHAMIDE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ADULT; AGED; ANCA ASSOCIATED SYSTEMIC VASCULITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MALE; MICROSCOPIC POLYANGIITIS; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; RELAPSE; REMISSION; SYSTEMIC VASCULITIS; TREATMENT RESPONSE; WEGENER GRANULOMATOSIS; ANCA ASSOCIATED VASCULITIS; DRUG ANTAGONISM; KIDNEY DISEASE; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PREDNISOLONE; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957240329     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq187     Document Type: Article

References (30)

1. Booth AD et al. Outcome of ANCA associated renal vasculitis: a 5 year retrospective study. Am J Kidney Dis 2003; 41: 776-784
2. Walton EW et al. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1985; 2: 265-270
3. Jayne D, Rasmussen N, Andrassy K et al. A randomized controlled trial of maintenance therapy for vasculitis associated with antineutro-phil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44
4. Gordon M, Luqmani RA, Adu D et al. Relapses in patients with a systemic vasculitis. Q J Med 1993; 86: 779-789
5. Chan AT, Flossmann O, Mukhtyar C, Jayne DR, Luqmani RA. The role of biologic therapies in the management of systemic vasculitis. Autoimmun Rev 2006; 5: 273-278
6. Huugen DH, Xiao A, Van Esch RJ et al. Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccaride: role of tumor necrosis factor-alpha. Am J Pathol 2005; 167: 47-58
7. Noronha IL, Kruger C, Andrassy K, Ritz E, Waldherr R. In situ production of TNFα, IL-1β and IL-2R in ANCA-positive glomerulone-phritis. Kidney Int 1993; 43: 682-692
8. Karkar AM, Smith J, Pusey CD. Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor-alpha. Nephrol Dial Transplant 2001; 6: 518-524
9. Booth AD, Jefferson HJ, Ayliffe W, Andrews PA, Jayne DR. Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis 2002; 61: 559
10. Bartolucci P, Ramanoelina J, Cohen P et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002; 41: 1126-1132
11. Lamprecht P, Voswinkel J, Lilienthal T et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's gran-ulomatosis. Rheumatology (Oxford) 2002; 41: 1303-1307
12. Booth A, Harper L, Hammad T et al. Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004; 15: 717-721
13. The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomato-sis. N Engl J Med 2005; 352: 351-361
14. Sandborn WJ, Hanauer S, Loftus EV Jr et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004; 99: 1984-1989
15. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance inflix-imab for Crohn's disease: the ACCENT 1 randomised trial. Lancet 2002; 359: 1541-1549
16. Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-1094
17. Burmester GR, Mariette X, Motecucco C et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007; 66: 732-739
18. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192
19. Luqmani RA, Bacon PA, Moots RJ et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994; 87: 671-678
20. De Groot K, Harper L, Jayne DRW et al. Pulse versus daily oral cy-clophosphamide for induction of remission in ANCA-associated vas-culitis. Ann Intern Med 2009; 150: 670-680
21. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470
22. Hoffman GS, Kerr GS, Leavitt RY et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-498
23. Mitoma H, Horiuchi T, Tsukamoto H et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008; 58: 1248-1257
24. Reinhold-Keller E, Beuge N, Latza U et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 1021-1032
25. Guillevin L, Cordier J-F, Lhote F. et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40: 2187-2198
26. Csernok E, Ernst M, Schmitt W, Bainton DF, Gross WL. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol 1994; 95: 244-250
27. Hess C, Sadallah S, Schifferli JA. Induction of neutrophil responsiveness to myeloperoxidase antibodies by their exposure to supernatant of degranulated autologous neutrophils. Blood 2000; 96: 2822-2827
28. Tomosugi NI, Cashman SJ, Hay H et al. Modulation of antibody-mediated glomerular injury in vivo by bacterial lipopolysaccharide, tumour necrosis factor, and IL-1. J Immunol 1989; 142: 3083-3090
29. Little MA, Smyth CL, Nakada MT, Cook HT, Nourshargh S, Pusey CD. Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol 2006; 17: 160-169
30. Booth AD, Jayne DR, Kharbanda RK et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 2004; 109: 1718-1723